US Patent

US9814708 — Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2

Formulation · Assigned to Auspex Pharmaceuticals Inc · Expires 2033-09-18 · 7y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects new pharmaceutical formulations of benzoquinoline compounds for treating chronic hyperkinetic movement disorders.

USPTO Abstract

The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.

Drugs covered by this patent

Austedo (DEUTETRABENAZINE) · Teva

Patent Metadata

Patent number: US9814708
Jurisdiction: US
Classification: Formulation
Expires: 2033-09-18
Drug substance claim: No
Drug product claim: Yes
Assignee: Auspex Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.